Patent ID: 11884723
Assignee: OSE IMMUNOTHERAPEUTICS
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A  Y | IPC A  C

Claim 2:
3. A method of treating a cancer in a subject that expresses SIRPa v1, the method comprising administering to a SIRPa v1 positive subject a therapeutic amount of an anti-human SIRPa antibody, antigen-binding fragment thereof, or modified antibody thereof, which comprises:
(a) a heavy chain variable domain comprising HCDR1, HCDR2 and HCDR3, wherein:
HCDR1 comprises the amino acid sequence set forth in SEQ ID NO: 9
HCDR2 comprises the amino acid sequence set forth in SEQ ID NO: 10 or SEQ ID NO: 11,
HCDR3 comprises the amino acid sequence set forth in SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, or SEQ ID NO: 15; and
(b) a light chain variable domain comprising of the amino acid sequence set forth in SEQ ID NO: 16 or SEQ ID NO: 17;
wherein the anti-human SIRPa antibody, antigen-binding fragment thereof, or modified antibody thereof inhibits the binding of human CD47 to human SIRPa v1 and does not prevent or inhibit the binding of human CD47 to human SIRPa v2.